ArticleBMC ophthalmology2025
Efficacy and safety of Nd: YAG laser vitreolysis in patients with physiological vitreous floaters.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Analysis of factors influencing the efficacy of YAG laser vitreolysis for symptomatic vitreous opacities and prediction of postoperative complication risks: a retrospective cohort study.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo observe the clinical effects of Nd: YAG laser vitreolysis in patients with physiological vitreous floaters by A/B ultrasound and infrared fundus photography., and to evaluate the safety of the treatment by ffERG.
methodsThirty eyes diagnosed with physiological vitreous floaters were enrolled. Examination of BCVA, IOP, SLO, A/B ultrasound, infrared fundus photography and ffERG were performed. The vitreolysis was performed for all patients by the same skilled doctor using an ELLEX YAG laser vitreolysis machine. The IOP was measured half an hour after the operation. After treatment, the patients were followed up at 1 day, 1 week, and 1 month. At follow-up, the same thorough examination as before the operation was performed. ImageJ software was used to measure the size of the vitreous floaters in the infrared fundus photography pictures before and after treatment.
resultsThere was no significant difference in BCVA and IOP before and after treatment (p > 0.05). Infrared fundus photography showed that the vitreous floaters were obviously reduced or disappeared after treatment, and the difference was statistically significant (p < 0.01). The latent period and amplitude of the five response waves of ffERG at each timepoint were compared before and after treatment, and there was no significant difference (P > 0.05). Ultra-wide angle SLO showed no severe complications in the vitreous or retina after treatment.
conclusionsIn short-term observations, Nd: YAG laser vitreolysis is safe and effective for the treatment of vitreous floaters and can be promoted clinically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.